Clinical significance of endogenous vasoactive neurohormones in chronic systolic heart failure

Journal of Cardiac Failure

Volumn 16, Issue 8, 2010, Pages 635-640

  Tang, W H Wilson ^a   Shrestha, Kevin ^a   Martin, Maureen G ^a   Borowski, Allen G ^a   Jasper, Sue ^a   Yandle, Timothy G ^b   Richards, A Mark ^b   Klein, Allan L ^a   Troughton, Richard W ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

endothelin; Heart failure; urocortin; urotensin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN 1; UROCORTIN I; UROTENSIN II;

ADULT; ARTICLE; CHRONIC DISEASE; CHRONIC SYSTOLIC HEART FAILURE; COHORT ANALYSIS; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MORTALITY; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC HEART FAILURE; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; AGED; BIOLOGICAL MARKERS; CHRONIC DISEASE; COHORT STUDIES; CORTICOTROPIN-RELEASING HORMONE; ENDOTHELIN-1; FEMALE; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; UROCORTINS;

EID: 77955516734     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2010.03.011     Document Type: Article

References (32)

1. W.H. Tang, R.H. Vagelos, Y.G. Yee, C.R. Benedict, K. Willson, and C.L. Liss Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure J Am Coll Cardiol 39 2002 70 78
2. N.S. Kirkby, P.W. Hadoke, A.J. Bagnall, and D.J. Webb The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 153 2008 1105 1119
3. J.C. Burnett Jr. Urocortin: advancing the neurohumoral hypothesis of heart failure Circulation 112 2005 3544 3546
4. L.L. Ng, I.W. Loke, R.J. O'Brien, I.B. Squire, and J.E. Davies Plasma urocortin in human systolic heart failure Clin Sci (Lond) 106 2004 383 388
5. M.E. Davis, C.J. Pemberton, T.G. Yandle, S.F. Fisher, J.G. Lainchbury, and C.M. Frampton Urocortin 2 infusion in human heart failure Eur Heart J 28 2007 2589 2597
6. M.T. Rademaker, V.A. Cameron, C.J. Charles, and A.M. Richards Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure Eur Heart J 27 2006 2088 2098
7. M.E. Davis, C.J. Pemberton, T.G. Yandle, J.G. Lainchbury, M.T. Rademaker, and M.G. Nicholls Effect of urocortin 1 infusion in humans with stable congestive cardiac failure Clin Sci (Lond) 109 2005 381 388
8. M.E. Davis, C.J. Pemberton, T.G. Yandle, J.G. Lainchbury, M.T. Rademaker, and M.G. Nicholls Urocortin-1 infusion in normal humans J Clin Endocrinol Metab 89 2004 1402 1409
9. S.Q. Khan, S.S. Bhandari, P. Quinn, J.E. Davies, and L.L. Ng Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans Int J Cardiol 117 2007 323 328
10. D. Gruson, M.F. Rousseau, S.A. Ahn, F. van Linden, and J.M. Ketelslegers Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers Peptides 27 2006 1527 1531
11. A.M. Richards, M.G. Nicholls, J.G. Lainchbury, S. Fisher, and T.G. Yandle Plasma urotensin II in heart failure Lancet 360 2002 545 546
12. L.L. Ng, I. Loke, R.J. O'Brien, I.B. Squire, and J.E. Davies Plasma urotensin in human systolic heart failure Circulation 106 2002 2877 2880
13. S.M. Gardiner, J.E. March, P.A. Kemp, J.J. Maguire, R.E. Kuc, and A.P. Davenport Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation Br J Pharmacol 147 2006 612 621
14. R.W. Troughton, D.L. Prior, C.M. Frampton, P.J. Nash, J.J. Pereira, and M. Martin Usefulness of tissue Doppler and color M-mode indexes of left ventricular diastolic function in predicting outcomes in systolic left ventricular heart failure (from the ADEPT study) Am J Cardiol 96 2005 257 262
15. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470
16. R.W. Troughton, D.L. Prior, J.J. Pereira, M. Martin, A. Fogarty, and A. Morehead Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function J Am Coll Cardiol 43 2004 416 422
17. J.J. Evans, A.H. Youssef, T.G. Yandle, L.K. Lewis, and M.G. Nicholls Effects of endothelin-1 on release of adrenomedullin and C-type natriuretic peptide from individual human vascular endothelial cells J Endocrinol 175 2002 225 232
18. S.F. Nagueh, C.P. Appleton, T.C. Gillebert, P.N. Marino, J.K. Oh, and O.A. Smiseth Recommendations for the evaluation of left ventricular diastolic function by echocardiography J Am Soc Echocardiogr 22 2009 107 133
19. S.P. Wright, R.N. Doughty, C.M. Frampton, G.D. Gamble, T.G. Yandle, and A.M. Richards Plasma urocortin 1 in human heart failure Circ Heart Fail 2 2009 465 471
20. M.T. Rademaker, C.J. Charles, and A.M. Richards Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure Am J Physiol Heart Circ Physiol 293 2007 H1536 H1544
21. M.T. Rademaker, C.J. Charles, M.G. Nicholls, and A.M. Richards Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure Clin Sci (Lond) 114 2008 635 642
22. M.T. Rademaker, C.J. Charles, E.A. Espiner, C.M. Frampton, J.G. Lainchbury, and A.M. Richards Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure Eur Heart J 26 2005 2055 2062
23. M.T. Rademaker, V.A. Cameron, C.J. Charles, and A.M. Richards Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure Circulation 112 2005 3624 3632
24. T.L. Bale, M. Hoshijima, Y. Gu, N. Dalton, K.R. Anderson, and K.F. Lee The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure Proc Natl Acad Sci U S A 101 2004 3697 3702
25. M.T. Rademaker, C.J. Charles, E.A. Espiner, S. Fisher, C.M. Frampton, and C.M. Kirkpatrick Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep J Am Coll Cardiol 40 2002 1495 1505
26. E. Sanz, N. Fernandez, L. Monge, B. Climent, G. Dieguez, and A.L. Garcia-Villalon Relaxation by urocortin of rat renal arteries: effects of diabetes in males and females Cardiovasc Res 58 2003 706 711 (Pubitemid 36694457)
27. M.T. Rademaker, C.J. Charles, E.A. Espiner, C.M. Frampton, J.G. Lainchbury, and A.M. Richards Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failure Eur Heart J 26 2005 2046 2054
28. D. Joyal, T. Huynh, N. Aiyar, B. Guida, S. Douglas, and A. Giaid Urotensin-II levels in acute coronary syndromes Int J Cardiol 108 2006 31 35
29. N. Bousette, F. Hu, E.H. Ohlstein, D. Dhanak, S.A. Douglas, and A. Giaid Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation J Mol Cell Cardiol 41 2006 285 295
30. A.Y. Zhang, Y.F. Chen, D.X. Zhang, F.X. Yi, J. Qi, and P. Andrade-Gordon Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney Am J Physiol Renal Physiol 285 2003 F792 F798
31. E. Ovcharenko, Z. Abassi, I. Rubinstein, A. Kaballa, A. Hoffman, and J. Winaver Renal effects of human urotensin-II in rats with experimental congestive heart failure Nephrol Dial Transplant 21 2006 1205 1211
32. S.C. Coste, R.F. Quintos, and M.P. Stenzel-Poore Corticotropin-releasing hormone-related peptides and receptors: emergent regulators of cardiovascular adaptations to stress Trends Cardiovasc Med 12 2002 176 182